title: The relationship between FGF-23 and ghrelin levels in CKD patients: preliminary data.
abstract: BACKGROUND
  Fibroblast growth factor (FGF)-23 is a recently discovered phosphaturic hormone that increases in chronic kidney disease (CKD). It has been accepted as a determinant of mortality and a therapeutic target in these patients. Ghrelin is a hormone that has roles in energy and nutrient metabolism. Ghrelin level was found to be increased in CKD patients. This is a controlled study in which the relationship between FGF-23 and ghrelin levels in CKD patients has been studied.
  
  
  METHODS
  Three groups were involved: 88 individuals. Dialysis group (DG, 33 patients) including patients on hemodialysis (21 patients) or peritoneal dialysis program (12 patients); predialysis group (PG, 29 patients) consisting of patients with stage-3 CKD; and the control group (CG, 29 individuals) of healthy adults. Serum FGF-23 and ghrelin levels were measured as well as routine biochemical parameters.
  
  
  RESULTS
  FGF-23 levels were similar within the groups (CG: 268±45 pg/mL, PG: 284±94 pg/mL, DG: 259±87 pg/mL, P=0.11). Ghrelin level was higher in the PG group compared with the DG and CG, while DG had higher ghrelin level than the CG (CG: 2.79±0.38 ng/mL, PG: 4.53±1.18 ng/mL, DG: 3.98±0.89 ng/mL). When all groups were studied together; a strong correlation was found between FGF-23 and ghrelin levels. When the analysis was repeated with PG and DG accepted as CKD group; this strong correlation persisted; while it was not true for the CG.
  
  
  CONCLUSIONS
  There might be a strong correlation between FGF-23 and ghrelin levels irrespective of the stage of CKD and the dialysis modality. There is need for further studies to clarify the pathophysiological link between these parameters.
authors.affiliation: Department of Nephrology, Haseki Training and Research Hospital, Istanbul, Turkey - savasozturkdr@yahoo.com.
authors.forename: Savas
authors.initials: S
authors.lastname: Ozturk
authors.forename: Oktay
authors.initials: O
authors.lastname: Ozkan
authors.forename: Murat
authors.initials: M
authors.lastname: Efe
authors.forename: Halil
authors.initials: H
authors.lastname: Yazici
authors.forename: Meltem
authors.initials: M
authors.lastname: Gursu
authors.forename: Ali Hakan
authors.initials: AH
authors.lastname: Kaya
authors.forename: Egemen
authors.initials: E
authors.lastname: Cebeci
authors.forename: Abdullah
authors.initials: A
authors.lastname: Sumnu
authors.forename: Serhat
authors.initials: S
authors.lastname: Karadag
authors.forename: Sule
authors.initials: S
authors.lastname: Poturoglu
authors.forename: Rumeyza
authors.initials: R
authors.lastname: Kazancioglu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D054439:Ghrelin / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000097:blood* / Q000628:therapy; D055815:Young Adult
chemical_list: D015415:Biomarkers; C000717427:FGF23 protein, human; D054439:Ghrelin; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23